Patents Assigned to Tolero Pharmaceuticals, Inc.
-
Publication number: 20200215071Abstract: Combination therapies for treatment of cancer are provided. The disclosed methods comprise administration of a cyclin-dependent kinase inhibitor and a DNA methyltransferase S inhibitor to a mammal in need thereof.Type: ApplicationFiled: March 17, 2020Publication date: July 9, 2020Applicant: TOLERO PHARMACEUTICALS, INC.Inventors: David J. Bearss, Steven L. Warner, Adam Siddiqui-Jain, Clifford J. Whatcott, Wontak Kim
-
Publication number: 20200200737Abstract: The present disclosure is generally directed to profiling peptides, compositions, and kits, as well as methods of use thereof. The profiling peptides comprise an Mcl-1 binding domain, and optionally a cellular uptake moiety. The methods of using such profiling peptides include predicting sensitivity of a cancer, selecting a treatment, treating a cancer, producing a sensitivity profile, and the like.Type: ApplicationFiled: August 20, 2019Publication date: June 25, 2020Applicant: Tolero Pharmaceuticals, Inc.Inventors: David J. BEARSS, Adam SIDDIQUI-JAIN, Clifford J. WHATCOTT, Peter W. PETERSON, Steven L. WARNER, Lars MOURITSEN
-
Patent number: 10682356Abstract: Combination therapies for treatment of cancer are provided. The disclosed methods comprise administration of a cyclin-dependent kinase inhibitor and a DNA methyltransferase inhibitor to a mammal in need thereof.Type: GrantFiled: October 28, 2019Date of Patent: June 16, 2020Assignee: TOLERO PHARMACEUTICALS, INC.Inventors: David J. Bearss, Steven L. Warner, Adam Siddiqui-Jain, Clifford J. Whatcott, Wontak Kim
-
Patent number: 10624880Abstract: The present disclosure provides diagnostic methods useful for predicting a patient's response to alvocidib and guiding a physician decision to administer alvocidib to the patient.Type: GrantFiled: May 29, 2019Date of Patent: April 21, 2020Assignee: Tolero Pharmaceuticals, Inc.Inventors: Steven L. Warner, David J. Bearss
-
Patent number: 10568887Abstract: Combination therapies for treatment of cancer are provided. The disclosed methods comprise administration of a cyclin-dependent kinase inhibitor and a DNA methyltransferase inhibitor to a mammal in need thereof.Type: GrantFiled: August 3, 2016Date of Patent: February 25, 2020Assignee: Tolero Pharmaceuticals, Inc.Inventors: David J. Bearss, Steven L. Warner, Adam Siddiqui-Jain, Clifford J. Whatcott, Wontak Kim
-
Patent number: 10562925Abstract: Compounds having the following structure (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein one of R1, R2 or R3 is —P(?O)(OH)2, and the other two of R1, R2 and R3 are each H, are provided. Pharmaceutical compositions comprising the compounds, and methods for use of the compounds for treating diseases associated with overexpression of a cyclin-dependent kinase (CDK) are also provided.Type: GrantFiled: February 19, 2019Date of Patent: February 18, 2020Assignee: TOLERO PHARMACEUTICALS, INC.Inventors: Adam Siddiqui-Jain, David J. Bearss
-
Patent number: 10472328Abstract: Compounds having activity as PKM2 activators are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.Type: GrantFiled: December 19, 2018Date of Patent: November 12, 2019Assignee: TOLERO PHARMACEUTICALS, INC.Inventors: Koc-Kan Ho, Yong Xu, Michael David Saunders, Xiaohui Liu, Scott Albert Pearce, Kevin Bret Wright, Jason Marc Foulks, Kenneth Mark Parnell, Steven Brian Kanner, David Lee Vollmer, Jihua Liu
-
Patent number: 10422788Abstract: The present disclosure is generally directed to profiling peptides, compositions, and kits, as well as methods of use thereof. The profiling peptides comprise an Mcl-1 binding domain, and optionally a cellular uptake moiety. The methods of using such profiling peptides include predicting sensitivity of a cancer, selecting a treatment, treating a cancer, producing a sensitivity profile, and the like.Type: GrantFiled: February 19, 2019Date of Patent: September 24, 2019Assignee: TOLERO PHARMACEUTICALS, INC.Inventors: David J. Bearss, Adam Siddiqui-Jain, Clifford J. Whatcott, Peter W. Peterson, Steven L. Warner, Lars Mouritsen
-
Publication number: 20190282557Abstract: The present disclosure provides diagnostic methods useful for predicting a patient's response to alvocidib and guiding a physician decision to administer alvocidib to the patient.Type: ApplicationFiled: May 29, 2019Publication date: September 19, 2019Applicant: Tolero Pharmaceuticals, Inc.Inventors: Steven L. Warner, David J. Bearss
-
Patent number: 10392392Abstract: The present invention provides substituted imidazo[1,2-b]pyridazines that are useful as protein kinase inhibitors and have one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. For example, a compound having the following structure: Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated conditions are also disclosed.Type: GrantFiled: July 11, 2018Date of Patent: August 27, 2019Assignee: Tolero Pharmaceuticals, Inc.Inventors: Yong Xu, Benjamin Gary Brenning, Steven G. Kultgen, Xiaohui Liu, Michael David Saunders, Koc-Kan Ho
-
Patent number: 10357488Abstract: The present disclosure provides diagnostic methods useful for predicting a patient's response to alvocidib and guiding a physician decision to administer alvocidib to the patient.Type: GrantFiled: September 14, 2018Date of Patent: July 23, 2019Assignee: Tolero Pharmaceuticals, Inc.Inventors: Steven L. Warner, David J. Bearss
-
Patent number: 10267787Abstract: The present disclosure is generally directed to profiling peptides, compositions, and kits, as well as methods of use thereof. The profiling peptides comprise an Mcl-1 binding domain, and optionally a cellular uptake moiety. The methods of using such profiling peptides include predicting sensitivity of a cancer, selecting a treatment, treating a cancer, producing a sensitivity profile, and the like.Type: GrantFiled: June 29, 2018Date of Patent: April 23, 2019Assignee: Tolero Pharmaceuticals, Inc.Inventors: David J. Bearss, Adam Siddiqui-Jain, Clifford J. Whatcott, Peter W. Peterson, Steven L. Warner, Lars Mouritsen
-
Patent number: 10259835Abstract: Compounds having the following structure (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein one of R1, R2 or R3 is —P(?O)(OH)2, and the other two of R1, R2 and R3 are each H, are provided. Pharmaceutical compositions comprising the compounds, and methods for use of the compounds for treating diseases associated with overexpression of a cyclin-dependent kinase (CDK) are also provided.Type: GrantFiled: August 9, 2017Date of Patent: April 16, 2019Assignee: Tolero Pharmaceuticals, Inc.Inventors: Adam Siddiqui-Jain, David J. Bearss
-
Patent number: 10207996Abstract: Compounds having activity as PKM2 activators are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.Type: GrantFiled: June 15, 2016Date of Patent: February 19, 2019Assignee: Tolero Pharmaceuticals, Inc.Inventors: Koc-Kan Ho, Yong Xu, Michael David Saunders, Xiaohui Liu, Scott Albert Pearce, Kevin Bret Wright, Jason Marc Foulks, Kenneth Mark Parnell, Steven Brian Kanner, David Lee Vollmer, Jihua Liu
-
Patent number: 10202356Abstract: Compounds having activity as inhibitors of ALK2 kinase and/or JAK2 kinase are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, X, z and A are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.Type: GrantFiled: March 13, 2014Date of Patent: February 12, 2019Assignee: Tolero Pharmaceuticals, Inc.Inventors: Alexis Mollard, Steven L. Warner, Gary A. Flynn, Hariprasad Vankayalapati, David J. Bearss
-
Patent number: 10132797Abstract: The present disclosure is generally directed to profiling peptides, compositions, and kits, as well as methods of use thereof. The profiling peptides comprise an Mcl-1 binding domain, and optionally a cellular uptake moiety. The methods of using such profiling peptides include predicting sensitivity of a cancer, selecting a treatment, treating a cancer, producing a sensitivity profile, and the like.Type: GrantFiled: December 19, 2017Date of Patent: November 20, 2018Assignee: Tolero Pharmaceuticals, Inc.Inventors: David J. Bearss, Adam Siddiqui-Jain, Clifford J. Whatcott, Peter W. Peterson, Steven L. Warner, Lars Mouritsen
-
Patent number: 10047093Abstract: The present invention provides protein kinase having one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated conditions are also disclosed.Type: GrantFiled: July 11, 2016Date of Patent: August 14, 2018Assignee: TOLERO PHARMACEUTICALS, INC.Inventors: Yong Xu, Benjamin Gary Brenning, Steven G. Kultgen, Xiaohui Liu, Michael David Saunders, Koc-Kan Ho
-
Patent number: 9901574Abstract: The present disclosure provides diagnostic methods useful for predicting a patient's response to alvocidib and guiding a physician decision to administer alvocidib to the patient.Type: GrantFiled: April 20, 2016Date of Patent: February 27, 2018Assignee: Tolero Pharmaceuticals, Inc.Inventors: Steven L. Warner, David J. Bearss
-
Patent number: 9758539Abstract: Compounds having the following structure (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein one of R1, R2 or R3 is —P(?O)(OH)2, and the other two of R1, R2 and R3 are each H, are provided. Pharmaceutical compositions comprising the compounds, and methods for use of the compounds for treating diseases associated with overexpression of a cyclin-dependent kinase (CDK) are also provided.Type: GrantFiled: May 18, 2016Date of Patent: September 12, 2017Assignee: Tolero Pharmaceuticals, Inc.Inventors: Adam Siddiqui-Jain, David J. Bearss
-
Patent number: 9714247Abstract: Kinase with inhibitory activity against kinases disposed in multiple signaling pathways and their therapeutic uses.Type: GrantFiled: September 26, 2016Date of Patent: July 25, 2017Assignees: Tolero Pharmaceuticals, Inc., Mannkind CorporationInventors: Qingping Zeng, Mary Faris, Alexis Mollard, Steven L. Warner, Gary A. Flynn
